Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial - The Lancet Haematology
Janssen and AbbVie's Imbruvica: fresh EC approvals
Heavy water labeling in CLL patients before ibrutinib therapy: workflow... | Download Scientific Diagram
Imbruvica 560 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)
These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. IMBRUVICA ® (ibrutinib) capsules, for oral use IMBRUVICA ® (ibrutinib) tablets,
Janssen's Imbruvica secures label expansion in Europe in chronic lymphocytic leukaemia | Pharmafile
Fourth breakthrough designation for Janssen's Imbruvica - PharmaTimes
BeiGene's Phase III Waldenström's study misses mark, but with a possible silver lining - MedCity News
Ibrutinib - Wikipedia
MCL - Study 1104 Study Design for R/R MCL | IMBRUVICA® (ibrutinib)
Imbruvica and Its Impact on Patients - WuXi XPress: for WuXi news and R&D insights
New Drug Product: IMBRUVICA - MPR
Imbruvica Full Prescribing Information, Dosage & Side Effects | MIMS Hong Kong
FDA expands Imbruvica's label to include survival data - PharmaTimes
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial - The Lancet Oncology
Imbruvica (ibrutinib) FDA Package Insert & Drug Facts - Iodine.com
RESONATE - Study Design | IMBRUVICA®
AbbVie's Imbruvica Expected to Become a Leading Oncology Drug
IMBRUVICA® (ibrutinib) - Cancer Therapy Advisor
Off-label Imbruvica Helped Ease CAD Symptoms, Preliminary Study Shows
BeiGene nabs landmark FDA nod for Brukinsa, kicking off challenge against blockbuster Imbruvica | FiercePharma
Supplemental Materials for Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study - The Lancet Oncology
